Abstract
Unlike first-generation non-nucleoside reverse transcriptase inhibitors (NNRTI), to develop complete resistance to etravirine (ETR), various mutations must be accumulated. This drug shows an intermediate barrier against partial resistance and a high barrier to complete resistance. Some mutations selected by nevirapine or efavirenz affect the activity of ETR, the most frequent being Y181C, G190A/S, K101E, L100I, Y188L and V90I. The grade of resistance conferred by each mutation differs. Currently, there are at least three lists of mutations that confer an exact score to each mutation. These lists have been validated with the grade of resistance observed in paired phenotypes and with clinical response in the DUET studies. The three scores show a high degree of agreement. ETR is currently one of the antiretroviral drugs whose activity can be calculated simply and accurately on the basis of genotypic data. The mutations selected after failure to nucleoside reverse transcriptase inhibitors, thymidine analogue, T69D/N and M184I/V, confer hypersusceptibility to ETR (fold change < 0.4) in up to 1 out of every 3 samples analyzed. The early withdrawal of first-generation NNRTIs in patients with virological failure is essential to avoid t...Continue Reading
References
Oct 9, 2002·AIDS·Richard H HaubrichUNKNOWN California Collaborative Treatment Group
Oct 9, 2002·AIDS·Jeannette M WhitcombChristos J Petropoulos
Jun 6, 2003·Journal of the American Chemical Society·Marina Udier-BlagovićWilliam L Jorgensen
Mar 5, 2004·The New England Journal of Medicine·François Clavel, Allan J Hance
Nov 25, 2004·Antimicrobial Agents and Chemotherapy·Koen AndriesMarie-Pierre de Béthune
Sep 29, 2005·Journal of Virology·Johan VingerhoetsMarie-Pierre de Béthune
Apr 7, 2007·AIDS·UNKNOWN TMC125-C223 Writing GroupBrian Woodfall
Jul 10, 2007·Lancet·José Valdez MadrugaUNKNOWN DUET-1 study group
Jul 10, 2007·Lancet·Adriano LazzarinBrian Woodfall
Jan 16, 2008·AIDS·Wendy P BannisterUNKNOWN EuroSIDA study group
Jan 18, 2008·HIV Medicine·A Cozzi-Lepri, UNKNOWN Standardization and Clinical Relevance of HIV Drug Resistance Testing Project for the Forum for Collaborative HIV Research
May 6, 2008·AIDS·C ScottM Nelson
May 13, 2008·Journal of Clinical Virology : the Official Publication of the Pan American Society for Clinical Virology·P SistaL Bacheler
Jun 14, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Martin S HirschDouglas D Richman
Jul 26, 2008·The Journal of Antimicrobial Chemotherapy·J M LlibreB Clotet
Oct 4, 2008·AIDS·Koen DeforcheUNKNOWN non-B Workgroup
Dec 18, 2008·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Karin J MetznerMatthias Cavassini
Dec 31, 2008·AIDS·Calvin J CohenBrian Woodfall
May 29, 2009·AIDS·Ron M KaganDale A Schwab